美托洛尔联合厄贝沙坦氢氯噻嗪治疗重症心力衰竭的疗效分析

目的探究美托洛尔联合厄贝沙坦氢氯噻嗪治疗重症心力衰竭的临床疗效。方法选取2017年4月至2020年4月本院收治的202例重症心力衰竭患者作为研究对象,按照随机数字表法分为对照组与研究组,各101例。对照组给予美托洛尔治疗,研究组在对照组基础上联合厄贝沙坦氢氯噻嗪治疗。比较两组治疗效果、心功能、血清NT-proBNP水平及不良反应发生率。结果研究组治疗总有效率为96.04%,高于对照组的80.20%(P<0.05)。用药前,两组心功能、血清NT-proBNP水平比较差异无统计学意义;用药后,两组LVESD、LVEDD、血清NT-proBNP均低于用药前,LVEF均高于用药前,且研究组LVESD、LVEDD、血清NT-proBNP均低于对照组,LVEF高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论美托洛尔联合厄贝沙坦氢氯噻嗪治疗重症心力衰竭患者疗效确切,可明显改善患者心功能,具有较高的安全性,值得临床推广应用。

Efficacy analysis of metoprolol combined with irbesartan and hydrochlorothiazide in the treatment of severe heart failure

Objective To explore the clinical efficacy of metoprolol combined with irbesartan and hydrochlorothiazide in the treatment of severe heart failure.Methods 202 patients with severe heart failure admitted to our hospital from April 2017 to April 2020 were selected as the research subjects,and they were divided into control group and study group according to random number table,with 101 cases in each group.The control group was treated with metoprolol,and the study group was treated with irbesartan and hydrochlorothiazide on the basis of the control group.The treatment effect,heart function,serum NT-proBNP level and the incidence of adverse reactions between the two groups were compared.Results The total effective rate of treatment in the study group was 96.04%,which was higher than 80.20 in the control group(P<0.05).Before medication,there was no statistically significant difference in cardiac function and serum NT-proBNP levels between the two groups;after medication,the LVESD,LVEDD,and serum NT-proBNP levels in the two groups were lower than before medication,and LVEF was higher than before medication,and the LVESD,LVEDD,serum NT-proBNP inthe study group were lower than those in the control group,and LVEF was higher than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion Metoprolol combined with irbesartan and hydrochlorothiazide has definite effect in the treatment of patients with severe heart failure,can significantly improve the heart function of patients,has high safety,and is worthy of clinical application.